Insulin aspart is a recombinant human insulin analog with rapid-acting blood glucoselowering activity produced by recombinant deoxyribonucleic acid (DNA) technology with an altered pharmacokinetic profile compared to endogenous human insulin. Structurally, it is a two-chain peptide comprising 51 amino acids, with the A-chain containing 21 amino acids and the B-chain containing 30 amino acids. It is identical to human insulin in primary structure except for a substitution of proline by aspartic acid at position B28. Clinically, insulin aspart is indicated for glycemic control in patients with diabetes mellitus type 1 (DMT1) and diabetes mellitus type 2 (DMT2), in both adult and pediatric populations.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value and the Permitted Daily Exposure (PDE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Insulin Aspart, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.